Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL) | Zendy

Wenqi Zhang | Zendy; Yanfeng Fan | Zendy; Meng Li | Zendy; Linqi Yang | Zendy; Zhenya Zhang | Zendy; Lihong Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)

Author(s) -

Wenqi Zhang,

Yanfeng Fan,

Meng Li,

Linqi Yang,

Zhenya Zhang,

Lihong Liu

Publication year - 2021

Publication title -

disease markers

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.912

H-Index - 66

eISSN - 1875-8630

pISSN - 0278-0240

DOI - 10.1155/2021/4894022

Subject(s) - cd47 , diffuse large b cell lymphoma , lymphoma , chop , medicine , oncology , cancer research , immunology , immune system

At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRP α axis to prevent tumor immune escape. Here, we evaluated the effects of the latest CD47 antibodies reported and the correlations of closely related genes with CD47 in this disease. In the future, therapeutic strategies for DLBCL will focus on multitarget antibody combined treatment and multigene joint attacks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research